The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...